JERUSALEM (Reuters) - Israeli drugmaker Kamada said on Monday it extended an agreement with Baxter International to supply a drug to treat emphysema through 2017. Under the extended agreement, Kamada said it will receive $26 million in additional revenues of Glassia, a proprietary drug to treat clinically evident emphysema in adults due to severe alpha-1-antitrypsin (AAT) deficiency. ...
via Health News Headlines - Yahoo News http://ift.tt/1BvlMM4
via Health News Headlines - Yahoo News http://ift.tt/1BvlMM4
No comments:
Post a Comment